New hope for kids with rare eye disease: targeted drug trial launches

NCT ID NCT07298928

First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 22 times

Summary

This study tests a new drug called Telitacicept in 30 children with ocular myasthenia gravis, a condition that causes eye muscle weakness and double vision. The goal is to see if the drug can better control symptoms and reduce the need for steroids, which have harsh side effects. Participants will receive the drug alongside their usual treatments, and researchers will track symptom improvement and safety over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EFFECTIVENESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital Affiliated to Shandong University

    Jinan, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shenzhen children's Hospital of China Medical University

    Shenzhen, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Children's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310052, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.